Reviva Pharmaceuticals (RVPH) Expected to Announce Earnings on Tuesday

Reviva Pharmaceuticals (NASDAQ:RVPH) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 13th. Analysts expect Reviva Pharmaceuticals to post earnings of ($0.21) per share for the quarter.

Reviva Pharmaceuticals (NASDAQ:RVPH) last released its quarterly earnings results on Monday, March 31st. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.07. On average, analysts expect Reviva Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Reviva Pharmaceuticals Price Performance

NASDAQ RVPH opened at $0.82 on Monday. The business’s fifty day moving average price is $0.87 and its 200-day moving average price is $1.35. The stock has a market capitalization of $38.31 million, a price-to-earnings ratio of -0.74 and a beta of 0.08. Reviva Pharmaceuticals has a 1-year low of $0.49 and a 1-year high of $4.28.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on RVPH. D. Boral Capital reaffirmed a “buy” rating and issued a $8.00 target price on shares of Reviva Pharmaceuticals in a report on Thursday, April 24th. HC Wainwright decreased their target price on Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating on the stock in a report on Wednesday, January 22nd. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $10.00.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.